Acrivon Therapeutics Correlations
| ACRV Stock | 8.83 0.76 7.92% |
The correlation of Acrivon Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acrivon Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acrivon Therapeutics Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Average diversification
The correlation between Acrivon Therapeutics Common and NYA is 0.12 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics Common and NYA in the same portfolio, assuming nothing else is changed.
Acrivon |
The ability to find closely correlated positions to Acrivon Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acrivon Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acrivon Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acrivon Therapeutics Common to buy it.
Moving together with Acrivon Stock
| 0.73 | CGC | Canopy Growth Corp Downward Rally | PairCorr |
| 0.77 | QLI | Qilian International | PairCorr |
| 0.7 | IMCC | Im Cannabis Corp | PairCorr |
Moving against Acrivon Stock
| 0.85 | TKNO | Alpha Teknova Financial Report 8th of May 2024 | PairCorr |
| 0.84 | PROC | Procaps Group SA Report 10th of May 2024 | PairCorr |
| 0.82 | GILD | Gilead Sciences | PairCorr |
| 0.82 | PROCW | Procaps Group SA | PairCorr |
| 0.81 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.79 | TAK | Takeda Pharmaceutical Sell-off Trend | PairCorr |
| 0.74 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.73 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
| 0.65 | RGC | Regencell Bioscience | PairCorr |
| 0.63 | CYTHW | Cyclo Therapeutics | PairCorr |
| 0.59 | ABBV | AbbVie Inc | PairCorr |
| 0.56 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.56 | OM | Outset MedicalInc Trending | PairCorr |
| 0.51 | AMGN | Amgen Inc | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Acrivon Stock performing well and Acrivon Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Acrivon Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Be your own money manager
Our tools can tell you how much better you can do entering a position in Acrivon Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Acrivon Therapeutics Corporate Management
Elected by the shareholders, the Acrivon Therapeutics' board of directors comprises two types of representatives: Acrivon Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acrivon. The board's role is to monitor Acrivon Therapeutics' management team and ensure that shareholders' interests are well served. Acrivon Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acrivon Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter MD | Chairman, CoFounder | Profile | |
| Jesper Olsen | Head CoFounder | Profile | |
| Dr MBA | Senior Affairs | Profile | |
| Katharine CPA | Vice Accounting | Profile | |
| Bruce Close | Vice Compliance | Profile | |
| MaryAlice JD | Chief Officer | Profile | |
| Crystal Mercado | Global HR | Profile |
Already Invested in Acrivon Therapeutics Common?
The danger of trading Acrivon Therapeutics Common is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acrivon Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acrivon Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acrivon Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Acrivon Therapeutics is a strong investment it is important to analyze Acrivon Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Acrivon Therapeutics' future performance. For an informed investment choice regarding Acrivon Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Acrivon Therapeutics Common. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Acrivon Stock analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Acrivon Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acrivon Therapeutics. If investors know Acrivon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acrivon Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Return On Assets (0.26) | Return On Equity (0.41) |
The market value of Acrivon Therapeutics is measured differently than its book value, which is the value of Acrivon that is recorded on the company's balance sheet. Investors also form their own opinion of Acrivon Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Acrivon Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acrivon Therapeutics' market value can be influenced by many factors that don't directly affect Acrivon Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acrivon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acrivon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acrivon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.